Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Recruiting

Early Phase 1

Nicotinamide RibosideStudy of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation

Sponsor:

Case Comprehensive Cancer Center

Code:

NCT04332341

Conditions

Allogeneic Hematopoietic Cell Transplantation

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nicotinamide riboside (NR)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-09-18. This information was provided to ClinicalTrials.gov by Case Comprehensive Cancer Center on 2025-04-16.